Total Payments
$151,308
2024 Payments
$25,534
Companies
27
Transactions
154
Medicare Patients
1,401
Medicare Billing
$160,609
Payment Breakdown by Category
Consulting$114,068 (75.4%)
Food & Beverage$14,862 (9.8%)
Other$12,021 (7.9%)
Travel$9,855 (6.5%)
Education$501.61 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $114,068 | 36 | 75.4% |
| Food and Beverage | $14,862 | 77 | 9.8% |
| Travel and Lodging | $9,855 | 31 | 6.5% |
| Honoraria | $6,900 | 3 | 4.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,121 | 3 | 3.4% |
| Education | $501.61 | 4 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $32,202 | 31 | $0 (2024) |
| PFIZER INC. | $26,392 | 16 | $0 (2024) |
| Clovis Oncology, Inc. | $18,312 | 37 | $0 (2022) |
| Astellas Pharma US Inc | $11,713 | 6 | $0 (2024) |
| pharmaand GmbH | $9,542 | 3 | $0 (2024) |
| Advanced Accelerator Applications | $8,534 | 3 | $0 (2022) |
| GENZYME CORPORATION | $8,504 | 8 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $6,566 | 10 | $0 (2024) |
| Janssen Biotech, Inc. | $5,975 | 10 | $0 (2023) |
| Astellas Pharma Global Development | $5,000 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $25,534 | 26 | pharmaand GmbH ($9,542) |
| 2023 | $34,883 | 23 | PFIZER INC. ($18,697) |
| 2022 | $17,889 | 17 | Bayer HealthCare Pharmaceuticals Inc. ($11,221) |
| 2021 | $12,382 | 15 | Bayer HealthCare Pharmaceuticals Inc. ($4,737) |
| 2020 | $14,183 | 6 | Bayer HealthCare Pharmaceuticals Inc. ($6,568) |
| 2019 | $35,782 | 48 | Clovis Oncology, Inc. ($14,035) |
| 2018 | $7,467 | 11 | Janssen Biotech, Inc. ($3,052) |
| 2017 | $3,188 | 8 | Ventana Medical Systems, Inc. ($2,073) |
All Payment Transactions
154 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Janssen Scientific Affairs, LLC | ERLEADA (Drug) | Consulting Fee | Cash or cash equivalent | $817.50 | General |
| Category: Oncology | ||||||
| 12/16/2024 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $2,450.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2024 | Tolmar, Inc. | — | Honoraria | Cash or cash equivalent | $1,800.00 | General |
| 12/05/2024 | pharmaand GmbH | Rubraca (Drug) | Food and Beverage | Cash or cash equivalent | $6,598.08 | General |
| Category: PARP inhibitor | ||||||
| 12/05/2024 | pharmaand GmbH | Rubraca (Drug) | Food and Beverage | Cash or cash equivalent | $2,800.00 | General |
| Category: PARP inhibitor | ||||||
| 11/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $86.28 | General |
| Category: Oncology | ||||||
| 11/12/2024 | pharmaand GmbH | Rubraca (Drug) | Food and Beverage | Cash or cash equivalent | $143.63 | General |
| Category: PARP inhibitor | ||||||
| 10/17/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $95.65 | General |
| Category: Oncology | ||||||
| 09/26/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $27.35 | General |
| Category: ONCOLOGY | ||||||
| 08/28/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: ONCOLOGY | ||||||
| 07/31/2024 | Astellas Pharma Global Development | Xtandi (Drug) | Consulting Fee | Cash or cash equivalent | $3,125.00 | General |
| Category: Oncology | ||||||
| 07/18/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $26.68 | General |
| Category: ONCOLOGY | ||||||
| 06/21/2024 | Janssen Scientific Affairs, LLC | BALVERSA (Drug) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: Oncology | ||||||
| 06/18/2024 | LANTHEUS MEDICAL IMAGING, INC. | — | Consulting Fee | Cash or cash equivalent | $1,510.00 | General |
| 06/01/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Food and Beverage | In-kind items and services | $161.65 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 05/09/2024 | LANTHEUS MEDICAL IMAGING, INC. | — | Food and Beverage | In-kind items and services | $97.27 | General |
| 04/24/2024 | Genentech USA, Inc. | Alecensa (Biological), Columvi, Lunsumio | Food and Beverage | In-kind items and services | $31.76 | General |
| Category: BioOncology | ||||||
| 04/10/2024 | LANTHEUS MEDICAL IMAGING, INC. | — | Food and Beverage | In-kind items and services | $98.83 | General |
| 03/27/2024 | Janssen Scientific Affairs, LLC | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $109.35 | General |
| Category: Oncology | ||||||
| 03/27/2024 | Janssen Scientific Affairs, LLC | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $29.15 | General |
| Category: Oncology | ||||||
| 03/19/2024 | LANTHEUS MEDICAL IMAGING, INC. | — | Consulting Fee | Cash or cash equivalent | $2,642.50 | General |
| 03/10/2024 | LANTHEUS MEDICAL IMAGING, INC. | — | Food and Beverage | In-kind items and services | $142.49 | General |
| 03/08/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $100.43 | General |
| Category: Oncology | ||||||
| 02/27/2024 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $18.00 | General |
| Category: ONCOLOGY | ||||||
| 02/12/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Food and Beverage | In-kind items and services | $129.02 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 242 | 280 | $113,022 | $26,115 |
| 2022 | 11 | 454 | 583 | $198,863 | $50,896 |
| 2021 | 5 | 327 | 459 | $62,415 | $46,171 |
| 2020 | 6 | 378 | 488 | $62,179 | $37,427 |
Total Patients
1,401
Total Services
1,810
Medicare Billing
$160,609
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 110 | 131 | $43,885 | $11,134 | 25.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 44 | 59 | $30,975 | $7,695 | 24.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 24 | 24 | $17,640 | $3,800 | 21.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 41 | 43 | $9,890 | $2,602 | 26.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 12 | 12 | $8,784 | $548.09 | 6.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 11 | 11 | $1,848 | $335.47 | 18.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 221 | 295 | $98,825 | $26,977 | 27.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 43 | 43 | $29,240 | $6,748 | 23.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 37 | 45 | $22,275 | $5,937 | 26.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 58 | 67 | $15,410 | $4,292 | 27.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 19 | 19 | $13,908 | $2,000 | 14.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 12 | 13 | $2,275 | $1,203 | 52.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 16 | 17 | $2,125 | $1,130 | 53.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 20 | $5,040 | $1,113 | 22.1% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 12 | 27 | $4,914 | $761.53 | 15.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 11 | 12 | $1,776 | $427.30 | 24.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 13 | 25 | $3,075 | $307.50 | 10.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 182 | 266 | $34,729 | $25,543 | 73.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 45 | 74 | $13,195 | $10,249 | 77.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 54 | 69 | $6,198 | $4,441 | 71.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 26 | 26 | $6,131 | $4,244 | 69.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 20 | 24 | $2,163 | $1,694 | 78.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 190 | 264 | $32,369 | $19,012 | 58.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 46 | 74 | $11,702 | $7,244 | 61.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 32 | 32 | $7,621 | $4,528 | 59.4% |
About Dr. Alan Bryce, M.D
Dr. Alan Bryce, M.D is a Hematology & Oncology healthcare provider based in Scottsdale, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/20/2005. The National Provider Identifier (NPI) number assigned to this provider is 1548246655.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alan Bryce, M.D has received a total of $151,308 in payments from pharmaceutical and medical device companies, with $25,534 received in 2024. These payments were reported across 154 transactions from 27 companies. The most common payment nature is "Consulting Fee" ($114,068).
As a Medicare-enrolled provider, Bryce has provided services to 1,401 Medicare beneficiaries, totaling 1,810 services with total Medicare billing of $160,609. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Hematology & Oncology
- Location Scottsdale, AZ
- Active Since 12/20/2005
- Last Updated 02/09/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1548246655
Products in Payments
- Nubeqa (Drug) $22,612
- Rubraca (Drug) $19,846
- TALZENNA (Drug) $11,812
- Xtandi (Drug) $9,847
- Xofigo (Drug) $9,590
- JEVTANA (Drug) $8,366
- RUBRACA (Drug) $8,007
- LORBRENA (Drug) $7,050
- Erleada (Drug) $5,372
- XTANDI (Drug) $3,850
- PLUVICTO (Drug) $3,475
- VENTANA RESEARCH & DEVELOPMENT (Device) $2,073
- ERLEADA (Drug) $1,853
- BAVENCIO (Drug) $1,600
- FOUNDATIONONE CDX (Device) $1,500
- LYNPARZA (Drug) $1,370
- Herceptin (Biological) $809.07
- PYLARIFY (Drug) $371.58
- IMBRUVICA (Drug) $168.79
- ZYTIGA (Drug) $154.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Scottsdale
Jeffrey Schriber, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Tanios Bekaii-Saab, M.d, M.D
Hematology & Oncology — Payments: $675,364
Hematology & Oncology $675,364
Dr. Rajesh Kukunoor, M.d, M.D
Hematology & Oncology — Payments: $515,496
Hematology & Oncology $515,496
Dr. Alexander Stewart, M.d, M.D
Hematology & Oncology — Payments: $291,151
Hematology & Oncology $291,151
Dr. Daniel Von Hoff, M.d, M.D
Hematology & Oncology — Payments: $248,837
Hematology & Oncology $248,837
Dr. Brendan Curley, D.o., M.p.h, D.O., M.P.H
Hematology & Oncology — Payments: $132,370
Hematology & Oncology $132,370